AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04919161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body weight support system with balance perturbations
Description: The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress.
Study NCT04408079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3558
Description: TQB3558 is a kinase inhibitor of the TRK protein family.
Study NCT03295916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
Study NCT02362451 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologus elutriated monocyte placebo vaccine
Description: 20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
Study NCT02362451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Description: 20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
Study NCT02476162 — intervention group
Intervention type: DEVICE
Intervention: iHealth Wireless Blood Pressure Monitor
Description: Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening.
Study NCT01245751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live
Description: Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
Study NCT02648906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate
Study NCT02648906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00620542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: capsule, oral, once daily
Study NCT00620542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: capsule, oral, one daily
Study NCT05104346 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: appendectomy
Description: open or laparoscopic appendectomy
Study NCT05104346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: open or laparoscopic appendectomy
Study NCT03573856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Living
Description: Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
Study NCT03573856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health and Safety
Description: Participants will be provided with education related to general health and safety topics.
Study NCT01319968 — intervention group
Intervention type: DRUG
Intervention: Estriol 0.1% vaginal cream
Description: Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
Study NCT02980796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice
Description: Each experimental day participants will complete a session of skilled motor practice.
Study NCT00198120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
Study NCT00198120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: same dosing schedule and capsule strength
Study NCT04553315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest expansion exercises
Description: Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
Study NCT03213236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Homemonitoring diagnostic system
Description: In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram.
Study NCT01348698 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor tissue biopsy
Description: Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
Study NCT01348698 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
Study NCT02388009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexyn2a
Description: Intramuscular doses of 0.5 mL
Study NCT02388009 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular doses of 0.5 mL
Study NCT02388009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexyn2a plus adjuvant
Description: Intramuscular doses of 0.5 mL
Study NCT03853928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII).
Study NCT03853928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII).
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake
Description: Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake
Description: Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Baby Toolkit
Description: The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army
Study NCT03423472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standart of care
Description: Government standard of care for nutrition education through the Health Development Army
Study NCT03035539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
Study NCT03035539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study NCT04172272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic multimodal analgesia administered intravenously
Description: Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.
Study NCT04172272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP block)
Description: The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.
Study NCT04172272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously
Description: TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
Study NCT03399292 — intervention group
Intervention type: DRUG
Intervention: Cationorm MD sine eye drops
Description: studyparticipants receive lipidbased eye drops once only in the study eye
Study NCT00820534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penciclovir
Description: Penciclovir every 2 hours during waking hours for 96 hours
Study NCT00820534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 2 hous during waking hours for 96 hours
Study NCT02600793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
Study NCT03831997 — intervention group
Intervention type: DRUG
Intervention: Dextrose 5% W/ Sodium Chloride 0.225%
Description: D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
Study NCT00886236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Study NCT00886236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Study NCT00886236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Study NCT02980796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice
Description: Each experimental day participants will complete a session of skilled motor practice.
Study NCT01525771 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Docetaxel
Description: The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days
Study NCT03253822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
Study NCT01230008 — intervention group
Intervention type: RADIATION
Intervention: no drugs
Description: Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
Study NCT03647007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11 for health
Description: The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
Study NCT00683995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246 (fentanyl citrate)
Study NCT01091207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The patients will receive daily oral administration of sorafenib 400 mg twice daily.
Study NCT03186365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zepatier Oral Product
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
Study NCT03186365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier Oral Product
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
Study NCT02043067 — intervention group
Intervention type: OTHER
Intervention: Comprehensive TB screening
Description: All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
Study NCT00442156 — intervention group
Intervention type: PROCEDURE
Intervention: Laser photocoagulation
Description: modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
Study NCT03578913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK crown
Description: The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
Study NCT03578913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEK crown
Description: The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
Study NCT03578913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM Crown
Description: Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
Study NCT03578913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM Crown
Description: Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
Study NCT04400747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
Study NCT01830686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse
Description: One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
Study NCT01830686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-caloric, non-fermentable fiber
Description: One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
Study NCT01830686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Minimal fiber
Description: One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative risk stratification
Description: Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
Study NCT02456389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative risk stratification
Description: Postoperative risk-prediction tool based on intraoperative variables
Study NCT04484168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Terminal Interruption of the Reflux Source
Description: Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
Study NCT04484168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axial Ablation
Description: Endovenous ablation of venous reflux in the main superficial veins of the leg
Study NCT00260611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00260611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere